UnitedHealth Group Re-Establishes Full Year Outlook and Reports Second Quarter 2025 Results • Full Year 2025 Revenue Outlook of $445.5 Billion to $448.0 Billion • Full Year 2025 Earnings Outlook of at least $14.65 Per Share, Adjusted Earnings of at least $16.00 Per Share • Second Quarter Earnings were $3.74 Per Share, Adjusted Earnings were $4.08 Per Share (July 29, 2025) UnitedHealth Group (NYSE: UNH) reported second quarter 2025 results and updated its 2025 outlook. “UnitedHealth Group has embarked on a rigorous path back to being a high-performing company fully serving the health needs of individuals and society broadly,” said Stephen Hemsley, chief executive officer of UnitedHealth Group. “As we strengthen operating disciplines, positioning us for growth in 2026 and beyond, the people at UnitedHealth Group will continue to support the millions of patients, physicians and customers who rely on us, guided by a culture of service and longstanding values.” On May 13, 2025, UnitedHealth Group suspended its 2025 outlook. Today, UnitedHealth Group is updating its 2025 outlook, including revenues of $445.5 billion to $448.0 billion, net earnings of at least $14.65 per share and adjusted earnings of at least $16.00 per share. The new outlook reflects first half 2025 performance and expectations for the remainder of the year, including higher realized and anticipated care trends. The company expects to return to earnings growth in 2026. Outlook components include: UnitedHealth Group 2025 Outlook ( $ in millions, except per share data ) Revenue Operating Earnings Optum $266,000 - $267,500 $12,550 - $12,850 UnitedHealthcare $344,000 - $345,500 $9,000 - $9,300 Eliminations ($164,500) - ($165,000) — Total UnitedHealth Group $445,500 - $448,000 $21,550 - $22,150 Diluted Adjusted (a) Net Earnings per Share At least $14.65 At least $16.00 (a) See page 15 of this release for a reconciliation of the non-GAAP measure. Additional 2025 outlook tables can be found on pages 3, 5 and 9 of this release. The company will provide additional details regarding current and planned actions on a teleconference for analysts and investors today at 8 a.m. ET. Page 1 of 16 Quarterly Financial Performance Three Months Ended June 30, June 30, March 31 2025 2024 2025 Revenues $111.6 billion $98.9 billion $109.6 billion Earnings from Operations $5.2 billion $7.9 billion $9.1 billion Net Margin 3.1% 4.3% 5.7% • UnitedHealth Group’s second quarter 2025 revenues grew $12.8 billion year-over-year to $111.6 billion, driven by growth within UnitedHealthcare and Optum. • Second quarter earnings from operations were $5.2 billion and adjusted net earnings were $4.08 per share. The second quarter results include $1.2 billion of unfavorable discrete impacts reflecting $620 million related to the individual exchange business, which includes the acceleration of future losses related to the second half of 2025, and several settlement and other provisions. • The second quarter consolidated medical care ratio of 89.4% increased 430 basis points year-over-year. The increase was primarily due to medical cost trends which significantly exceeded pricing trends, including both unit costs and the intensity of services delivered, and the ongoing effects of Medicare funding reductions. Medical reserve development was $70 million unfavorable in the second quarter 2025, with nearly all related to 2025 dates of service. The full year 2025 medical cost ratio is now expected to be 89.25% +/- 25 basis points. • Days claims payable of 44.5 compared to 45.5 in the first quarter 2025 and 45.2 in second quarter 2024. The decline was driven by the Medicare Part D program changes. Days sales outstanding declined 1.6 days year-over-year and 2.4 days sequentially on customer payment timing. • The second quarter 2025 operating cost ratio of 12.3% compared to 13.3% in the year ago quarter reflecting business mix, inclusive of the Part D program changes, reduced impacts from last year’s Change Healthcare cyberattack and cost management activities. The full year 2025 operating cost ratio is now expected to be 12.75% +/- 25 basis points. • The lower tax expense in the second quarter 2025 reflects the year-to-date impact of the updated full year effective tax rate expectation. The full year 2025 tax rate is now expected to be ~18.5%, affected by the revised earnings outlook while the expected tax benefit levels remain steady. • In June, the company increased its quarterly dividend rate by 5% to $2.21 and returned $4.5 billion to shareholders through dividends and share repurchases in the second quarter. UnitedHealth Group’s annualized return on equity through the first six months of 2025 was 20.6%, and the June 30, 2025 ratio of debt to total capital was 44.1%. • Cash flows from operations were $7.2 billion in second quarter 2025, or 2.0 times net income. Page 2 of 16 UnitedHealthcare provides health care benefits globally, serving individuals and employers, and Medicare and Medicaid beneficiaries. UnitedHealthcare is dedicated to improving the value customers and consumers receive by improving health and wellness, enhancing the quality of care received, simplifying the health care experience and reducing the total cost of care. UnitedHealthcare 2025 Outlook ($ in millions; membership in thousands) Revenues: Employer & Individual $79,600 - $80,100 Medicare & Retirement $170,200 - $170,700 Community & State $94,200 - $94,700 Total UnitedHealthcare Revenue $344,000 - $345,500 Operating Earnings $9,000 - $9,300 Operating Margin 2.6% - 2.7% UnitedHealthcare People Served Growth in People Served Total People Served Commercial Risk (385) 8,460 Commercial Fee 720 21,605 Total Commercial 335 30,065 Medicare Advantage 650 8,495 Standardized Medicare Supplement (50) 4,285 Medicaid 200 7,635 Total Medical 1,135 50,480 Stand-Alone Part D Prescription Drug Plans (300) 2,750 • Full year 2025 revenues for UnitedHealthcare are expected to range from $344.0 billion to $345.5 billion, growth of more than 15% over 2024. Earnings from operations are expected to be in the range of $9.0 billion to $9.3 billion . • “While we face challenges across our lines of business, we believe we can resolve these issues and recapture our earnings growth potential while ensuring people have access to high-quality, affordable health care,” said Tim Noel, UnitedHealthcare chief executive officer. • The number of people served with medical benefits is expected to increase by up to 1.135 million over 2024, led by serving seniors and people with complex needs. The number of people served with commercial benefits is expected to increase by up to 335,000, with growth of 720,000 within self-funded employer-sponsored offerings. The number of people served with commercial insured offerings is expected to decline by 385,000, comprised of 180,000 contraction in individual insured offerings, of which 140,000 are on exchange products, and a decline of 205,000 in employer-sponsored group products. Page 3 of 16 UnitedHealthcare Business Results - Continued Quarterly Financial Performance Three Months Ended June 30, June 30, March 31, 2025 2024 2025 Revenues $86.1 billion $73.9 billion $84.6 billion Earnings from Operations $2.1 billion $4.0 billion $5.2 billion Operating Margin 2.4% 5.4% 6.2% • UnitedHealthcare’s second quarter 2025 revenue of $86.1 billion grew $12.2 billion or 17% year-over-year. UnitedHealthcare served 50 million people in the second quarter 2025, an increase of 770,000 year-to-date. – UnitedHealthcare Employer & Individual second quarter 2025 revenues of $19.8 billion compared to $19.2 billion in second quarter 2024, with growth driven by commercial offerings. The number of people served increased by 400,000 year-over-year, with growth in employer self-funded offerings of 695,000 partially offset by attrition in both individual and group fully-insured products. – UnitedHealthcare Medicare & Retirement second quarter 2025 revenues of $42.6 billion grew $7.7 billion or 22% year-over-year due to Part D IRA impacts and growth in the number of people served. People served with individual and group Medicare Advantage offerings grew 505,000 through the first half of 2025, while Medicare Supplement contracted by 30,000 through the first half of 2025 and Standalone Part D plans decreased by 250,000 through the first half of 2025. – UnitedHealthcare Community & State second quarter 2025 revenues of $23.7 billion grew 20% year-over-year, driven by growth in serving people with complex needs and Medicaid rate improvements. Members served grew by 55,000 through the first half of 2025 to a total of 7.5 million people. The company now serves a total of 32 states and D.C. • Second quarter 2025 earnings from operations for UnitedHealthcare were $2.1 billion compared to $4.0 billion in second quarter 2024. Second quarter 2025 operating margin of 2.4% compared to 5.4% in second quarter 2024. This was primarily due to higher-than-expected medical cost trend across the UnitedHealthcare businesses and the effects of the Medicare funding reductions. • The higher medical trends are being driven by both an increase in units consumed and rapidly rising costs per patient encounter, which includes both the unit cost and the number, type and intensity of services being delivered having increased well beyond the pricing and benefit design considerations established last year. For example, medical cost trend in Medicare Advantage offerings is expected to run at ~7.5% in 2025 compared to the 2025 pricing expectation of just over 5%. The pricing and benefit designs for 2026 anticipate these trends to continue to accelerate meaningfully to nearly 10%. UnitedHealthcare is committed to providing high-quality, affordable health offerings for the people it serves and is working to deliver effective solutions in the current, unprecedented medical cost trend environment. Page 4 of 16 The Optum health services businesses serve the global health care marketplace, including payers, care providers, employers, governments, life sciences companies and consumers. Using market-leading information, analytics and technology to yield clinical insights, Optum helps improve overall health system performance by optimizing care quality, reducing care costs and improving the consumer experience. Optum 2025 Outlook ($ in millions) Revenues Operating Earnings Operating Margin Optum Health $101,100 - $101,600 $3,000 - $3,100 3.0% - 3.1% Optum Insight $19,000 - $19,500 $3,550 - $3,650 18.2% - 19.2% Optum Rx $151,000 - $151,500 $6,000 - $6,100 4.0% Eliminations ($5,100) Total Optum $266,000 - $267,500 $12,550 - $12,850 4.7% - 4.8% Optum Performance Metrics Optum Health Fully Accountable Value-Based Care Patients 5 million Optum Insight Revenue Backlog $32.0 billion Optum Rx Adjusted Scripts 1.67 billion • “We know Optum’s performance has not met expectations. We are refocused on fundamental execution to ensure we meet our potential to help make the health system work better for everyone,” said Dr. Patrick Conway, Optum chief executive officer. Optum Health • Full year 2025 revenues for Optum Health are expected to be $101.1 billion to $101.6 billion, a decline of 4% over 2024. Earnings from operations are expected to be $3.0 billion to $3.1 billion. The full year operating earnings margin is estimated at 3.0% to 3.1%. • The number of patients served under fully accountable value-based care models is now expected to increase by ~300,000 to 5 million. The company has intentionally reduced its planned 2025 expansion in new patients served from the initial 650,000 view to 300,000 to better focus on the geographies, practices and clinicians with the most developed capabilities and to strengthen operational execution across the platform. Optum Insight • Full year 2025 Optum Insight revenues are expected to range from $19.0 billion to $19.5 billion compared to $18.8 billion in 2024. Earnings from operations are expected to be $3.55 billion to $3.65 billion. The full year operating earnings margin is estimated at 18.2% to 19.2% and the contract revenue backlog is expected to be $32.0 billion. Optum Rx • Full year 2025 Optum Rx revenues are expected to be $151.0 billion to $151.5 billion compared to $133.2 billion a year ago, with the increase driven by continued strong growth in customers and people served across the company’s integrated pharmacy services offerings. Earnings from operations are expected to be $6.0 billion to $6.1 billion. The full year operating margin is estimated at 4.0% and adjusted scripts are expected to be 1.67 billion. Page 5 of 16 Optum Business Results – Continued Quarterly Financial Performance Three Months Ended June 30, June 30, March 31, 2025 2024 2025 Revenues $67.2 billion $62.9 billion $63.9 billion Earnings from Operations $3.1 billion $3.9 billion $3.9 billion Operating Margin 4.6% 6.2% 6.1% Optum Health • Optum Health’s second quarter 2025 revenue of $25.2 billion decreased $1.8 billion or 7% year-over-year, driven by the legacy customer contract revisions cited in first quarter 2025 and effects related to the Medicare Advantage funding cuts. • Second quarter earnings from operations were $636 million compared to $1.9 billion in the year ago quarter and operating margins were 2.5% and 7.1%, respectively. The decline was due to higher medical care activity, the flow through effects from underpriced health plan offerings where the company assumes full risk, including the impacts of the Medicare funding reductions and under-estimation of the V-28 risk model transition, and the mix of newly served patients. Optum Insight • Optum Insight’s second quarter 2025 revenue of $4.8 billion increased 6% year-over-year driven by a diverse portfolio of technology and data driven offerings. • Second quarter earnings from operations were $998 million compared to $546 million a year ago and operating margins were 20.7% and 12.0%, respectively, due to reduced impacts from the Change Healthcare cyberattack, a favorable mix of the types of services and products being purchased by customers and improved operating efficiencies. The contract revenue backlog was $32.1 billion. Optum Rx • Optum Rx’s second quarter 2025 revenue of $38.5 billion increased 19% year-over-year driven by growth in new clients and expansion in existing client relationships. • Earnings from operations for second quarter 2025 were $1.4 billion compared to $1.4 billion a year ago and operating margins were 3.7% and 4.3%, respectively. The operating margin decline year-over-year was primarily due to higher revenue in the second quarter 2025 offset by increased fulfillment of high-cost drugs and the impact of the initial launch of the private label business. Adjusted scripts grew to 414 million compared to 399 million last year. Page 6 of 16 About UnitedHealth Group UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at www.unitedhealthgroup.com and follow UnitedHealth Group on LinkedIn. Earnings Conference Call As previously announced, UnitedHealth Group will discuss the company’s results, strategy and future outlook on a conference call with investors at 8:00 a.m. Eastern Time today. UnitedHealth Group will host a live webcast of this conference call from the Investor Relations page of the company’s website (www.unitedhealthgroup.com). Following the call, a webcast replay will be on the Investor Relations page through August 12, 2025. This earnings release and the Form 8-K dated July 29, 2025, can also be accessed from the Investor Relations page of the company’s website. Non-GAAP Financial Information This news release presents non-GAAP financial information provided as a complement to the results provided in accordance with accounting principles generally accepted in the United States of America (“GAAP”). A reconciliation of the non-GAAP financial information to the most directly comparable GAAP financial measure is provided in the accompanying tables found at the end of this release. Forward-Looking Statements The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities laws. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify forward-looking statements. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or application; cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; the DOJ’s legal actions concerning our participation in the Medicare program; our ability to maintain and achieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; risks and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to our public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of potential changes in tax laws and regulations; increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to complete, manage or integrate strategic transactions; risk and uncertainties associated with the sale of our remaining operations in South America; risks associated with public health crises arising from large-scale medical emergencies, pandemics, natural disasters and other extreme events; failure to attract, develop, retain, and manage the succession of key employees and executives; our investment portfolio performance; impairment of our goodwill and intangible assets; failure to protect proprietary rights to our databases, software and related products; downgrades in our credit ratings; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, reinvest in our business, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock. This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial condition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements, except as required by law. Investors: Media: investor_relations@uhg.com uhgmedia@uhg.com Page 7 of 16 UNITEDHEALTH GROUP Earnings Release Schedules and Supplementary Information Quarter Ended June 30, 2025 • Supplemental Financial Information - 2025 Outlook • Condensed Consolidated Statements of Operations • Condensed Consolidated Balance Sheets • Condensed Consolidated Statements of Cash Flows • Supplemental Financial Information - Businesses • Supplemental Financial Information - People Served and Performance Metrics • Reconciliation of Non-GAAP Financial Measure Page 8 of 16 UNITEDHEALTH GROUP SUPPLEMENTAL FINANCIAL INFORMATION - 2025 OUTLOOK ($ and weighted-average shares in millions; except per share data) Projected Year Ended December 31, 2025 Revenues: Optum $266,000 - $267,500 UnitedHealthcare 344,000 - 345,500 Eliminations (164,500) - (165,000) Total consolidated revenue $445,500 - $448,000 Earnings from operations: Optum $12,550 - $12,850 UnitedHealthcare 9,000 - 9,300 Total consolidated operating earnings $21,550 - $22,150 Investment and other income ~$4,400 Interest expense ~$4,200 Depreciation and amortization ~$4,300 Net earnings attributable to UnitedHealth Group common shareholders At least $13,350 Diluted weighted-average shares outstanding 912 - 914 Diluted earnings per share attributable to UnitedHealth Group common shareholders At least $14.65 Adjusted earnings per share attributable to UnitedHealth Group common shareholders (a) At least $16.00 Medical care ratio 89.25% +/- 25 bps Operating cost ratio 12.75% +/- 25 bps Operating margin 4.8% - 5.0% Tax rate ~18.5% Cash flows from operations ~$16,000 (a) See page 15 for a reconciliation of the non-GAAP measure. Page 9 of 16 UNITEDHEALTH GROUP CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share data; unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenues Premiums $87,905 $76,897 $174,439 $154,885 Products 13,564 12,211 26,600 24,120 Services 9,039 8,750 18,011 17,638 Investment and other income 1,108 997 2,141 2,008 Total revenues 111,616 98,855 221,191 198,651 Operating costs Medical costs 78,585 65,458 151,996 131,193 Operating costs 13,778 13,162 27,372 27,239 Cost of products sold 13,019 11,340 25,409 22,396 Depreciation and amortization 1,084 1,020 2,145 2,017 Total operating costs 106,466 90,980 206,922 182,845 Earnings from operations 5,150 7,875 14,269 15,806 Interest expense (1,027) (985) (2,025) (1,829) Loss on sale of subsidiary and subsidiaries held for sale (41) (1,225) (56) (8,311) Earnings before income taxes 4,082 5,665 12,188 5,666 Provision for income taxes (510) (1,244) (2,142) (2,466) Net earnings 3,572 4,421 10,046 3,200 Earnings attributable to noncontrolling interests (166) (205) (348) (393) Net earnings attributable to UnitedHealth Group common shareholders $3,406 $4,216 $9,698 $2,807 Diluted earnings per share attributable to UnitedHealth Group common shareholders $3.74 $4.54 $10.61 $3.02 Adjusted earnings per share attributable to UnitedHealth Group common shareholders (a) $4.08 $6.80 $11.29 $13.71 Diluted weighted-average common shares outstanding 910 928 914 929 (a) See page 15 for a reconciliation of the non-GAAP measure. Page 10 of 16 UNITEDHEALTH GROUP CONDENSED CONSOLIDATED BALANCE SHEETS (in millions; unaudited) June 30, 2025 December 31, 2024 Assets Cash and short-term investments $32,020 $29,113 Accounts receivable, net 24,142 22,365 Other current assets 37,537 34,301 Total current assets 93,699 85,779 Long-term investments 52,466 52,354 Other long-term assets 162,408 160,145 Total assets $308,573 $298,278 Liabilities, redeemable noncontrolling interests and equity Medical costs payable $38,427 $34,224 Short-term borrowings and current maturities of long-term debt 5,698 4,545 Other current liabilities 66,656 65,000 Total current liabilities 110,781 103,769 Long-term debt, less current maturities 73,495 72,359 Other long-term liabilities 19,513 19,559 Redeemable noncontrolling interests 4,315 4,323 Equity 100,469 98,268 Total liabilities, redeemable noncontrolling interests and equity $308,573 $298,278 Page 11 of 16 UNITEDHEALTH GROUP CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions; unaudited) Six Months Ended June 30, 2025 2024 Operating Activities Net earnings $10,046 $3,200 Noncash items: Depreciation and amortization 2,145 2,017 Deferred income taxes and other 40 101 Share-based compensation 572 594 Loss on sale of subsidiary and subsidiaries held for sale 56 8,311 Net changes in operating assets and liabilities (215) (6,333) Cash flows from operating activities 12,644 7,890 Investing Activities Sales and maturities of investments, net of purchases (purchases of investments, net of sales and maturities) 1,327 (221) Purchases of property, equipment and capitalized software (1,784) (1,596) Cash paid for acquisitions and other transactions, net (734) (3,031) Loans to care providers - cyberattack — (8,100) Repayments of care provider loans - cyberattack 1,293 604 Other, net (1,618) (1,413) Cash flows used for investing activities (1,516) (13,757) Financing Activities Common share repurchases (5,545) (3,072) Dividends paid (3,912) (3,664) Net change in short-term borrowings and long-term debt 1,566 12,790 Other, net 43 981 Cash flows (used for) from financing activities (7,848) 7,035 Effect of exchange rate changes on cash and cash equivalents 29 (44) Increase in cash and cash equivalents, including cash within businesses held for sale 3,309 1,124 Less: net increase in cash within businesses held for sale (25) (265) Net increase in cash and cash equivalents 3,284 859 Cash and cash equivalents, beginning of period 25,312 25,427 Cash and cash equivalents, end of period $28,596 $26,286 Page 12 of 16 UNITEDHEALTH GROUP SUPPLEMENTAL FINANCIAL INFORMATION - BUSINESSES (in millions, except percentages) (unaudited) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenues UnitedHealthcare $86,103 $73,866 $170,720 $149,223 Optum 67,225 62,879 131,110 123,931 Eliminations (41,712) (37,890) (80,639) (74,503) Total consolidated revenues $111,616 $98,855 $221,191 $198,651 Earnings from Operations UnitedHealthcare $2,075 $4,004 $7,301 $8,399 Optum (a) 3,075 3,871 6,968 7,407 Total consolidated earnings from operations $5,150 $7,875 $14,269 $15,806 Operating Margin UnitedHealthcare 2.4 % 5.4 % 4.3 % 5.6 % Optum 4.6 % 6.2 % 5.3 % 6.0 % Consolidated operating margin 4.6 % 8.0 % 6.5 % 8.0 % Revenues UnitedHealthcare Employer & Individual - Domestic $18,950 $18,646 $38,016 $36,485 UnitedHealthcare Employer & Individual - Global 819 591 1,601 2,123 UnitedHealthcare Employer & Individual - Total 19,769 19,237 39,617 38,608 UnitedHealthcare Medicare & Retirement 42,623 34,904 84,328 70,390 UnitedHealthcare Community & State 23,711 19,725 46,775 40,225 Optum Health $25,205 $27,050 $50,514 $53,781 Optum Insight 4,828 4,543 9,458 9,045 Optum Rx 38,459 32,415 73,591 63,250 Optum eliminations (1,267) (1,129) (2,453) (2,145) (a) Earnings from operations for Optum for the three and six months ended June 30, 2025 included $636 and $2,250 for Optum Health; $998 and $1,959 for Optum Insight; and $1,441 and $2,759 for Optum Rx, respectively. Earnings from operations for Optum for the three and six months ended June 30, 2024 included $1,919 and $3,818 for Optum Health; $546 and $1,036 for Optum Insight; and $1,406 and $2,553 for Optum Rx, respectively. Page 13 of 16 UNITEDHEALTH GROUP SUPPLEMENTAL FINANCIAL INFORMATION - PEOPLE SERVED AND PERFORMANCE METRICS (unaudited) UnitedHealthcare Customer Profile (in thousands) People Served June 30, 2025 March 31, 2025 December 31, 2024 June 30, 2024 Commercial: Risk-based 8,440 8,410 8,845 8,735 Fee-based 21,530 21,590 20,885 20,835 Total Commercial 29,970 30,000 29,730 29,570 Medicare Advantage 8,350 8,245 7,845 7,770 Medicaid 7,490 7,570 7,435 7,410 Medicare Supplement (Standardized) 4,305 4,310 4,335 4,335 Total Community and Senior 20,145 20,125 19,615 19,515 Total UnitedHealthcare - Medical 50,115 50,125 49,345 49,085 Supplemental Data Medicare Part D stand-alone 2,800 2,835 3,050 3,065 South American businesses held for sale 1,165 1,160 1,330 1,330 Optum Performance Metrics June 30, 2025 March 31, 2025 December 31, 2024 June 30, 2024 Optum Health Consumers Served (in millions) 98 99 100 104 Optum Insight Contract Backlog (in billions) $32.1 $32.9 $32.8 $32.6 Optum Rx Quarterly Adjusted Scripts (in millions) 414 408 422 399 Page 14 of 16 UNITEDHEALTH GROUP RECONCILIATION OF NON-GAAP FINANCIAL MEASURE Use of Non-GAAP Financial Measure Adjusted net earnings per share is a non-GAAP financial measure. Non-GAAP financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP. Adjustments to adjusted net earnings per share are as follows: Intangible Amortization : As amortization fluctuates based on the size and timing of the company’s acquisition activity, management believes this exclusion provides a more useful comparison of the company’s underlying business performance and trends from period to period. While intangible assets contribute to the Company’s revenue generation, the intangible amortization is not directly related. Therefore, the related revenues are included in adjusted earnings per share. South American Impacts: The loss on the sale of our Brazilian operations completed on February 6, 2024, the loss on our remaining South American operations being classified as held for sale and certain other non-recurring matters impacting our South American operations are not representative of the Company’s underlying business performance and therefore management believes the exclusion presents a more useful comparison of the Company’s underlying business performance and trends from period to period. Direct Response Costs - Cyberattack: Management believes the exclusion of costs incurred to investigate and remediate the attack, other direct and incremental costs incurred as a result of the cyberattack and incremental costs for accommodations to support care providers presents a more useful comparison of the Company’s underlying business performance and trends from period to period. Page 15 of 16 UNITEDHEALTH GROUP RECONCILIATION OF NON-GAAP FINANCIAL MEASURE (in millions, except per share data; unaudited) Adjusted Net Earnings Per Share Three Months Ended June 30, Six Months Ended June 30, Projected Year Ended December 31, 2025 2024 2025 2024 2025 Net earnings attributable to UnitedHealth Group common shareholders $3,406 $4,216 $9,698 $2,807 At least $13,350 Intangible amortization 409 417 826 816 ~1,625 Tax effect of intangible amortization (99) (103) (201) (201) ~(400) South American impacts — 1,340 — 8,426 — Tax effect of South American impacts — (157) — (157) — Direct response costs - cyberattack — 776 — 1,369 — Tax effect of direct response costs - cyberattack — (182) — (323) — Adjusted net earnings attributable to UnitedHealth Group common shareholders $3,716 $6,307 $10,323 $12,737 At least $14,575 Diluted earnings per share $3.74 $4.54 $10.61 $3.02 At least $14.65 Intangible amortization per share 0.45 0.45 0.90 0.88 ~1.75 Tax effect of intangible amortization per share (0.11) (0.11) (0.22) (0.22) ~(0.40) South American impacts per share — 1.45 — 9.07 — Tax effect of South American impacts per share — (0.17) — (0.17) — Direct response costs - cyberattack per share — 0.84 — 1.47 — Tax effects of direct response costs - cyberattack per share — (0.20) — (0.34) — Adjusted diluted earnings per share $4.08 $6.80 $11.29 $13.71 At least $16.00 Page 16 of 16

the item shown at left

other guidance in this release

Text is the filed exhibit, verbatim.